Trials / Completed
CompletedNCT04335344
Role of suPAR in Periodontitis and CVD
Evaluation of Plasma and Salivary suPAR in Periodontitis and CVD Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 326 (actual)
- Sponsor
- University of Messina · Academic / Other
- Sex
- All
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum suPAR levels.
Detailed description
The aim of this study was to evaluate a possible association between both saliva and serum suPAR levels in patients with CP and with CVD and if the serum suPAR levels are mediated by serum CRP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observation of suPAR plasma and salivary levels | Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease |
Timeline
- Start date
- 2015-02-15
- Primary completion
- 2018-09-21
- Completion
- 2020-02-25
- First posted
- 2020-04-06
- Last updated
- 2020-04-07
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04335344. Inclusion in this directory is not an endorsement.